Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Alun Parson"'
Autor:
Pedro Casado, Ana Rio-Machin, Juho J. Miettinen, Findlay Bewicke-Copley, Kevin Rouault-Pierre, Szilvia Krizsan, Alun Parsons, Vinothini Rajeeve, Farideh Miraki-Moud, David C. Taussig, Csaba Bödör, John Gribben, Caroline Heckman, Jude Fitzgibbon, Pedro R. Cutillas
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-14 (2023)
Abstract Acute myeloid leukaemia (AML) patients harbouring certain chromosome abnormalities have particularly adverse prognosis. For these patients, targeted therapies have not yet made a significant clinical impact. To understand the molecular lands
Externí odkaz:
https://doaj.org/article/5e487f8d5d7f4d8e866dad9751eee848
Autor:
Disha Malani, Olli Kallioniemi, Alun Parson, Satu Mustjoki, Minna Suvela, Caroline A. Heckman, Katja Suomi, Karoliina Laamanen, Laura Turunen, Kimmo Porkka, Ashwni Kumar, Bjørn Tore Gjertsen, Imre Vastrik, Muntasir Mamun Majumder, Pekka Ellonen, Evgeny Kulesskiy, Maija Wolf, Maria Nurmi, Oscar Brück, Astrid Muruimägi, Swapnil Potdar, Sari Kytölä, Krister Wennerberg, Samuli Eldfors, Tero Aittokallio, Simon Anders, Riikka Karjalainen, Bhagwan Yadav, Jani Saarela, Siv Knappila, Matti Kankainen, Aino Palva, Elina Lehtinen, Mika Kontro, Pirkko Mattila
Publikováno v:
Cancer Research. 79:458-458
Acute myeloid leukemia (AML) is an aggressive disease of clonal hematopoietic progenitor cells. Here, we applied ex-vivo drug sensitivity and resistance testing on AML patient cells with 362 emerging and 153 approved cancer drugs together with genomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12a633a44f8cc531db67e03f23b7b7c5
https://doi.org/10.1158/1538-7445.am2019-458
https://doi.org/10.1158/1538-7445.am2019-458
Autor:
Siv Knappila, Matti Kankainen, Aino Palva, Piia Mikkonen, Maria Nurmi, Imre Vastrik, Mika Kontro, Karjalainen Riikka, Sanna Timonen, Satu Mustjoki, Krister Wennerberg, Disha Malani, Maija Wolf, Oscar Brück, Pekka Ellonen, Ashwini Kumar, Tero Aittokallio, Pirkko Mattila, Laura Turunen, Caroline A. Heckman, Bhagwan Yadav, Karoliina Laamanen, Kimmo Porkka, Sari Kytölä, Swapnil Potdar, Alun Parson, Poojitha Ojamies, Astrid Murumägi, Evgeny Kulesskiy, Bjorn Tore Gjersten, Olli Kallioniemi, Muntasir Mamun Majumder, Minna Suvela, Jani Saarela, Samuli Eldfors, Simon Anders, Elina Lehtinen
Publikováno v:
Cancer Research. 78:3899-3899
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by multiple molecular subtypes and lack of effective targeted therapies. Here, we performed extensive molecular profiling and ex vivo drug testing with 515 approved and emerging ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8441d7b389f0b3f097b06cb0766d1c78
https://doi.org/10.1158/1538-7445.am2018-3899
https://doi.org/10.1158/1538-7445.am2018-3899
Autor:
Jarno Kivioja, Disha Malani, Ashwini Kumar, Mika Kontro, Alun Parsons, Olli Kallioniemi, Caroline A. Heckman
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract FLT3 internal tandem duplication (FLT3-ITD) is a frequent mutation in acute myeloid leukemia (AML) and remains a strong prognostic factor due to high rate of disease recurrence. Several FLT3-targeted agents have been developed, but determina
Externí odkaz:
https://doaj.org/article/b265a741e37b4d01bbabcd8866e60edf
Autor:
Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta, Amanda Ranta, Jani Huuhtanen, Minna Suvela, Alun Parsons, Annasofia Holopainen, Anu Partanen, Milla E.L. Kuusisto, Sirpa Koskela, Riikka Räty, Maija Itälä-Remes, Imre Västrik, Olli Dufva, Sanna Siitonen, Kimmo Porkka, Krister Wennerberg, Caroline A. Heckman, Pia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Mika Kontro
Publikováno v:
Haematologica, Vol 108, Iss 7 (2022)
The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particular
Externí odkaz:
https://doaj.org/article/ed146fcdf2474b39baf1bf345a6c2b2c
Autor:
Minxia Liu, Yinyin Wang, Juho J. Miettinen, Romika Kumari, Muntasir Mamun Majumder, Ciara Tierney, Despina Bazou, Alun Parsons, Minna Suvela, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, Paul Dowling, Peter O’Gorman, Jing Tang, Caroline A. Heckman
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Despite several new therapeutic options, multiple myeloma (MM) patients experience multiple relapses and inevitably become refractory to treatment. Insights into drug resistance mechanisms may lead to the development of novel treatment strategies. Th
Externí odkaz:
https://doaj.org/article/ebd1a0e2671e4755b6242ea4919a4c67
Autor:
Muntasir M. Majumder, Aino-Maija Leppä, Monica Hellesøy, Paul Dowling, Alina Malyutina, Reidun Kopperud, Despina Bazou, Emma Andersson, Alun Parsons, Jing Tang, Olli Kallioniemi, Satu Mustjoki, Peter O’Gorman, Krister Wennerberg, Kimmo Porkka, Bjørn T. Gjertsen, Caroline A. Heckman
Publikováno v:
Haematologica, Vol 105, Iss 6 (2020)
Innate drug sensitivity in healthy cells aids identification of lineage specific anti-cancer therapies and reveals off-target effects. To characterize the diversity in drug responses in the major hematopoietic cell types, we simultaneously assessed t
Externí odkaz:
https://doaj.org/article/584985b275234eb4b42bd82b31d24a90
Autor:
Ashwini Kumar, Matti Kankainen, Alun Parsons, Olli Kallioniemi, Pirkko Mattila, Caroline A. Heckman
Publikováno v:
BMC Genomics, Vol 18, Iss 1, Pp 1-13 (2017)
Abstract Background RNA sequencing (RNA-seq) has become an indispensable tool to identify disease associated transcriptional profiles and determine the molecular underpinnings of diseases. However, the broad adaptation of the methodology into the cli
Externí odkaz:
https://doaj.org/article/0ae52d828a7d4dfab89cc8e7d40cfb75